The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression
The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression
复制标题
DOI：
10.1007/s00262-011-1159-3
复制
发表时间：
2012-06-01
影响因子：
5.8
通讯作者：
Kraaij, Robert
中科院分区：
文献类型：
--
作者：
Schroten, Caroline;Dits, Natasja F.;Kraaij, Robert
考虑到前列腺癌发病率在未来几年将增加的事实，需要关于诊断的前列腺癌的生物侵袭性的新的预后生物标志物。由于细胞因子与癌症的生物学和预后有关，我们确定了转化生长因子β 1是否TGF-β 1、白细胞介素-7（IL-7）受体和IL-7水平增加了关于前列腺癌特异性生存率的额外预后信息。对44例接受根治性前列腺癌切除术的前列腺癌患者进行回顾性生存分析（1989-2001）。收集年龄、Gleason评分和治疗前PSA水平。通过定量实时RT-PCR测定前列腺癌组织中的IL-7、IL-7受体和TGF β 1水平，并分析其与前列腺癌生存率的额外预后价值。估计风险比及其置信区间，计算Akaike的信息标准用于模型比较。当TGF β 1和IL-7加入到仅包含Gleason评分和治疗前PSA的模型中时，模型对前列腺癌生存率的预测能力增加了一倍以上（AIC：18.1和AIC：6.5）JL-7和TGF β 1是有希望的标志物，用于指示那些处于前列腺癌存活率差的风险中的人。关于诊断的前列腺癌的生物侵袭性，特别是对于那些筛查前列腺癌的患者及其考虑的治疗，该额外信息可能是感兴趣的。
Given the fact that prostate cancer incidence will increase in the coming years, new prognostic biomarkers are needed with regard to the biological aggressiveness of the prostate cancer diagnosed. Since cytokines have been associated with the biology of cancer and its prognosis, we determined whether transforming growth factor beta 1 (TGF beta 1), interleukin-7 (IL-7) receptor and IL-7 levels add additional prognostic information with regard to prostate cancer-specific survival.Retrospective survival analysis of forty-four prostate cancer patients, that underwent radical prostatectomy, was performed (1989-2001). Age, Gleason score and pre-treatment PSA levels were collected. IL-7, IL-7 receptor and TGF beta 1 levels in prostate cancer tissue were determined by quantitative real-time RT-PCR and their additional prognostic value analyzed with regard to prostate cancer survival. Hazard ratios and their confidence intervals were estimated, and Akaike's information criterion was calculated for model comparison.The predictive ability of a model for prostate cancer survival more than doubled when TGF beta 1 and IL-7 were added to a model containing only the Gleason score and pre-treatment PSA (AIC: 18.1 and AIC: 6.5, respectively).IL-7 and TGF beta 1 are promising markers to indicate those at risk for poor prostate cancer survival. This additional information may be of interest with regard to the biological aggressiveness of the diagnosed prostate cancer, especially for those patients screened for prostate cancer and their considered therapy.